These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 16730273

  • 1. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA, Lebwohl D.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [Abstract] [Full Text] [Related]

  • 2. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
    Clin Cancer Res; 2005 Jul 15; 11(14):5319-28. PubMed ID: 16033851
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ, Jelovac D, Thiantanawat A, Brodie AM.
    Clin Cancer Res; 2002 Jul 15; 8(7):2378-88. PubMed ID: 12114443
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
    Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.
    J Clin Oncol; 2009 Mar 20; 27(9):1382-7. PubMed ID: 19224856
    [Abstract] [Full Text] [Related]

  • 7. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM.
    Expert Rev Anticancer Ther; 2007 May 20; 7(5):627-34. PubMed ID: 17492927
    [Abstract] [Full Text] [Related]

  • 8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 9. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU, Vergote I, Sainsbury R.
    Breast J; 2004 Feb 10; 10(3):211-7. PubMed ID: 15125747
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 10; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 13. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
    Núñez NP, Jelovac D, Macedo L, Berrigan D, Perkins SN, Hursting SD, Barrett JC, Brodie A.
    Clin Cancer Res; 2004 Aug 15; 10(16):5375-80. PubMed ID: 15328175
    [Abstract] [Full Text] [Related]

  • 14. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
    Foster PA, Chander SK, Newman SP, Woo LW, Sutcliffe OB, Bubert C, Zhou D, Chen S, Potter BV, Reed MJ, Purohit A.
    Clin Cancer Res; 2008 Oct 15; 14(20):6469-77. PubMed ID: 18927286
    [Abstract] [Full Text] [Related]

  • 15. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
    Awada A, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M.
    Eur J Cancer; 2008 Jan 15; 44(1):84-91. PubMed ID: 18039566
    [Abstract] [Full Text] [Related]

  • 16. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS.
    Breast; 2006 Feb 15; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A.
    Clin Cancer Res; 2007 May 01; 13(9):2751-7. PubMed ID: 17473209
    [Abstract] [Full Text] [Related]

  • 19. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
    Nair HB, Kirma NB, Ganapathy M, Vadlamudi RK, Tekmal RR.
    Steroids; 2011 Jul 01; 76(8):792-6. PubMed ID: 21477609
    [Abstract] [Full Text] [Related]

  • 20. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
    Thomas JS, Julian HS, Green RV, Cameron DA, Dixon MJ.
    Histopathology; 2007 Aug 01; 51(2):219-26. PubMed ID: 17650216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.